Lazard Asset Management LLC Eagle Pharmaceuticals, Inc. Transaction History

Lazard Asset Management LLC

$68.3 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$25.06 - $34.09 $8,846 - $12,033	-353 Reduced 7.51%	4,350 $123,000
Q4 2022 Feb 14, 2023	BUY	$24.98 - $39.77 $9,317 - $14,834	373 Added 8.61%	4,703 $137,000
Q2 2022 Aug 09, 2022	BUY	$41.26 - $51.35 $79,466 - $98,900	1,926 Added 80.12%	4,330 $192,000
Q1 2022 May 13, 2022	SELL	$44.58 - $52.6 $44 - $52	-1 Reduced 0.04%	2,404 $118,000
Q4 2021 Feb 09, 2022	BUY	$45.82 - $56.9 $11,363 - $14,111	248 Added 11.5%	2,405 $122,000
Q3 2021 Nov 15, 2021	BUY	$43.79 - $55.78 $94,455 - $120,317	2,157 New	2,157 $120,000
Q1 2021 May 14, 2021	SELL	$40.32 - $50.97 $64,915 - $82,061	-1,610 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$41.72 - $51.34 $62,037 - $76,342	1,487 Added 1208.94%	1,610 $74,000
Q3 2020 Nov 13, 2020	SELL	$37.02 - $51.28 $42,721 - $59,177	-1,154 Reduced 90.37%	123 $5,000
Q2 2020 Aug 13, 2020	BUY	$43.24 - $55.02 $55,217 - $70,260	1,277 New	1,277 $61,000
Q3 2018 Nov 13, 2018	SELL	$66.65 - $83.86 $21.5 Million - $27 Million	-322,340 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$51.25 - $76.62 $98,246 - $146,880	-1,917 Reduced 0.59%	322,340 $24.4 Million
Q1 2018 May 14, 2018	SELL	$52.16 - $66.86 $2.26 Million - $2.89 Million	-43,240 Reduced 11.77%	324,257 $17.1 Million
Q4 2017 Feb 13, 2018	BUY	$49.6 - $60.87 $784,870 - $963,206	15,824 Added 4.5%	367,497 $19.6 Million
Q3 2017 Nov 13, 2017	BUY	$46.62 - $60.36 $3.42 Million - $4.43 Million	73,391 Added 26.37%	351,673 $21 Million
Q2 2017 Aug 19, 2019	BUY	N/A	254,007 Added 1046.37%	278,282 $22 Million
Q1 2017 Aug 13, 2019	SELL	N/A	-9,125 Reduced 27.32%	24,275 $2.01 Million
Q2 2016 Jul 29, 2019	BUY	N/A	33,400	33,400 $1.3 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.35M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $11.7M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Account